SELLAS Life Sciences Group, Inc. (SLS) stock
SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.95−1.20 (-6.27%)
Close on Nov 18, 2026Market cap $3.62BP/E –Yield –
SELLAS Life Sciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
SELLAS Life Sciences's operating income for the twelve months ending Jun 30, 2026 was -$35.22M. For fiscal 2025 it was -$28.27M. The highest annual figure on record is -$12.49M in fiscal 2011.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$28.27M | – |
| FY2024 | Dec 31, 2024 | -$31.51M | – |
| FY2023 | Dec 31, 2023 | -$37.87M | – |
| FY2022 | Dec 31, 2022 | -$41.95M | – |
| FY2021 | Dec 31, 2021 | -$25.29M | – |
| FY2020 | Dec 31, 2020 | -$16.98M | – |
| FY2019 | Dec 31, 2019 | -$20.04M | – |
| FY2017 | Dec 31, 2017 | -$23.04M | – |
| FY2016 | Dec 31, 2016 | -$15.99M | – |
| FY2015 | Dec 31, 2015 | -$34.22M | – |
| FY2014 | Dec 31, 2014 | -$43.90M | – |
| FY2013 | Dec 31, 2013 | -$28.49M | – |
| FY2012 | Dec 31, 2012 | -$21.20M | – |
| FY2011 | Dec 31, 2011 | -$12.49M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.63M | – |
| Q1 FY2026 | Mar 31, 2026 | -$9.25M | – |
| Q4 FY2025 | Dec 31, 2025 | -$8.26M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.08M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.87M | – |
| Q1 FY2025 | Mar 31, 2025 | -$6.06M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.92M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.33M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.62M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.65M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.18M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.05M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.28M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.45M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.15M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.62M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.74M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.62M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.98M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.45M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.25M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.16M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.49M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.27M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.06M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.58M | -198.1% |
| Q3 FY2017 | Sep 30, 2017 | -$4.46M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.91M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.09M | – |
| Q4 FY2016 | Dec 31, 2016 | $8.74M | – |
| Q3 FY2016 | Sep 30, 2016 | -$6.47M | – |
See a number that looks wrong?